Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Non-Current Assets (2019 - 2025)

BridgeBio Pharma's Other Non-Current Assets history spans 7 years, with the latest figure at $16.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 8.15% year-over-year to $16.7 million; the TTM value through Dec 2025 reached $16.7 million, down 8.15%, while the annual FY2025 figure was $16.7 million, 8.15% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $16.7 million at BridgeBio Pharma, down from $25.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $49.8 million in Q2 2021 and bottomed at $16.6 million in Q1 2025.
  • The 5-year median for Other Non-Current Assets is $20.7 million (2023), against an average of $25.0 million.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 188.61% in 2021 before it tumbled 41.21% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $33.0 million in 2021, then crashed by 38.77% to $20.2 million in 2022, then grew by 11.87% to $22.6 million in 2023, then decreased by 19.58% to $18.2 million in 2024, then dropped by 8.15% to $16.7 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Other Non-Current Assets are $16.7 million (Q4 2025), $25.5 million (Q3 2025), and $18.1 million (Q2 2025).